• 1

Epidermolysis Bullosa – Allogeneic

We are recruiting patients with recessive dystrophic Epidermolysis bullosa (RDEB) for an international multicentric phase I/IIa clinical trial.

The aim of the trial is to examine the efficacy and safety of allogeneic ABCB5-positive mesenchymal stem cells (ABCB5+ MSCs) in patients suffering from RDEB. Primary endpoints are the overall improvement of EB symptoms (as measured by percentage change of the EBDASI score) and the occurrence of adverse events.

For this trial 18 patients will be recruited in the USA, UK, Austria, France, Italy and Germany. The trial has been approved by the U.S. Food and Drug Administration (FDA) and the other respective competent national regulatory authorities. The European Medicines Agency (EMA) and the U.S. FDA have granted RHEACELL’s ABCB5+ MSC product Orphan Drug Designation for the treatment of Epidermolysis bullosa.

For the manufacturing process of the allogeneic ABCB5+ MSCs we are using a patent hold by the Brigham and Women’s Hospital, Boston/USA, and the Children’s Hospital, Boston/USA, in cooperation with our scientific partner Prof. Dr. Markus Frank.

More information about the trial can be found HERE (ClinicalTrials.gov) or HERE (EU Clinical Trials Register).

Background information about the use of ABCB5+ MSCs in EB can be found HERE.

<< back

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.